Patent Application
20090047241
The present invention relates in general to hematopoiesis and stem cell transplantation. More specifically, the invention provides compositions and methods for promoting the recovery of patients' bone marrow micro-environment after disease- or treatment-induced damage.
Severe myelosuppression is a common side effect of radiotherapy or chemotherapy. Methods have been developed to protect patients by stimulating white blood cell or red blood cell recovery/production using growth factors such as G-CSF or EPO. However, there is no available means to stimulate the full lineage blood cell recovery from severe myelosuppression.
The hematopoietic stem cell (HSC) compartment resides in the bone marrow and produces full lineage blood cells throughout the lifespan. A functional hematopoietic system relies on HSC and their supporting microenvironment/niche. Via direct cell-cell interaction or soluble factors produced locally or systemically, the microenvironment regulates the quiescence, apoptosis, self-renewal, proliferation and differentiation of stem cells [1-4]. The mechanism for this complicated regulation remains largely unknown. Accumulated evidence has shown that, as a niche component, osteoblasts play a pivotal role in HSC regulation [5-8]. Recently, using different approaches, two groups demonstrated that sinusoidal endothelial cells are another important element of the niche [9,10]. It has been shown that disruption of osteoblasts or sinusoidal endothelial cells results in the hematopoiesis dysfunction. On the other hand, stimulation of the osteoblasts or sinusoil endothelial cells leads to increase of HSC numbers [6,8,9] or recovery of HSC from myelosuppession [10].
Bone marrow is the most sensitive organ to ionizing radiation and/or chemotherapeutic drugs during cancer therapy. Myelosuppression and hematopoietic dysfunction are the most common clinical complications following radio-/chemo-therapy. These physical or chemical insults can damage hematopoiesis by targeting either HSC directly or alternatively their microenvironment or both. Obviously, it is important in cancer treatment to promote the recovery of hematopoiesis from myelosuppression.
Consequently, a number of cytokines and combinations of cytokines have been studied using lethally irradiated animals [11-18]. Most of the studies observed the animal survival for 30 days after lethal radiation. With a combination of 5 anti-apoptotic factors, Herodin et al. reported 50% long-term survival (360 days) of the rescued animals. The receptors of the factors used in the previous studies, such as SCF, SDF-1, TPO, and Flt-3 ligand, are expressed on the HSC/progenitor cells. The protection from these factors may be a direct effect on the stem/progenitor cells. However, in the GI system, the FGF-2 mediated radioprotective effect on intestinal crypt stem cells is via the protection of the endothelial cells adjacent to crypt stem cells, since FGF-2 receptor could only be detected on endothelial cells [19]. Since HSC function is closely related to the structure and function of microenvironment, the recovery of hematopoiesis from lethal radiation requires the recovery of both the microenvironment and the HSC.
Interleukin-12 (IL-12) is a heterodimeric pro-inflammatory cytokine that regulates the activity of cells involved in the immune response [20-22]. It stimulates the production of IFN-y from natural killer cells and T cells, favors the differentiation of T helper 1 cells, and forms a link between innate resistance and adaptive immunity. Under in vitro conditions, IL-12 can stimulate the hematopoiesis synergistically with IL-3 and SCF [23,24]. It has been reported that, at the price of sensitizing the GI system, IL-12 can protect the bone marrow from lethal irradiation [15]. However, in contrast to other radioprotective factors that may stimulate tumor cell proliferation or angiogenesis, such as SCF, SDF-1 and FGF-1[25-28], IL-12 inhibits tumor cell growth [29] and is anti-angiogenic [30,31].
In accordance with one embodiment, the invention relates to compositions comprising IL-12 that promote the recovery of hematopoeisis in damaged bone marrow cells.
In accordance with another embodiment, the invention relates to compositions comprising IL-12 that protect bone marrow from radiation and/or chemotherapy.
In accordance with a related embodiment, the invention relates to compositions comprising IL-12 that are useful as an hematopoietic-protecting agent.
In accordance with yet another embodiment, the invention relates to compositions comprising IL-12 that are useful in the treatment of cancer.
In one embodiment, the invention relates to methods of using compositions comprising IL-12 to promote the recovery of hematopoeisis in damaged bone marrow cells.
In another embodiment, the invention relates to methods of using compositions comprising IL-12 to protect bone marrow from radiation and/or chemotherapy.
In a related embodiment, the invention relates to methods of using compositions comprising IL-12 as an hematopoietic-protecting agent.
In yet another embodiment, the invention relates to methods of using compositions comprising IL-12 to treat cancer.
In a further embodiment, the invention relates to compositions comprising IL-12 that protect the bone marrow microenvironment from the damage caused by radiation and/or chemotherapy.
In another further embodiment, the invention relates to methods of using compositions comprising IL-12 to protect the bone marrow microenvironment from the damage caused by radiation and/or chemotherapy.
In a further related embodiment, the invention provides methods to facilitate the engraftment of stem cell transplantation.
The above-mentioned and other features of this invention and the manner of obtaining and using them will become more apparent, and will be best understood, by reference to the following description, taken in conjunction with the accompanying drawings. The drawings depict only typical embodiments of the invention and do not therefore limit its scope.
(a) Lin− cells were stained with FITC-conjugated anti-Sca-1 and APC-conjugated anti-c-kit antibodies for FACS analysis; (b) Lin−Sca+c-kit+ Cells (in gate R2) were reanalyzed for IL-12 receptor expression by staining with PE-conjugated anti-IL-12 receptor β2 chain antibody.
(c) cDNAs from 4 individual sorted samples with 5000 of Lin−Sca+c-kit+CD34− cells in each were analyzed for the expression of IL-12 receptor and CD3e, β-actin expression was used as internal control. The first lane was no RT control and the second lane was RT-PCR from bone marrow Lin− cells as positive control for IL-12 receptor and CD3e. Lanes 1-4 were results from 4 individual sorted samples.
Bone marrow/hematopoietic stem cell transplantation has been widely applied to treat both malignant and non-malignant diseases. In most of the cases, conditional regimen, high dose of chemotherapy treatment or combination of chemotherapy and radiation, is required. The purpose of this regimen is to kill the malignant cells and/or eliminate the host immune-system resulted rejection to the donor cells. However, in this process, the recipients bone marrow are severe impaired, which leads to various side effects, including bone marrow failure. The other commonly seen complication in stem cell transplantation is the engraftment failure, meaning that the donor cells can not proliferate and repopulate the blood system after transplantation. Based on the statistical summary, the successful engraftment rate with allogeneic stem cell transplantation is about 40-60%. The HSC engraftment failure may result from various reasons. Besides the quantity and quality of transplanted stem cell, the bone marrow microenvironment plays key role in the success of the HSC transplantation.
When transplanted HSC home to bone marrow, cells in bone marrow microenvironment provide the support for the HSC growth and proliferation. It has been reported that transplantation of non-HSC bone marrow cells resulted in a better engraftment of HSC in transplantation. The inventors show that IL-12 can facilitate the HSC engraftment by protecting the bone marrow microenvironment from the damage of conditional regimen, which ultimately facilitates the engraftment of HSC.
Currently, there is no effective method to facilitate the engraftment of stem cells in the stem cell transplantation. To improve the success rate of stem cell transplantation, large efforts has been put into the stem cell ex vivo expansion. In animal model, it has been reported that co-transplantation of other bone marrow cellular components, such as mesenchymal stem cells, may increase the chance of success in stem cell transplantation. However, both methods are premature and require cellular component, which increase the difficulty for clinical application.
The inventors have provided a simple but effective method to facilitate the engraftment of stem cell transplantation. By injection of IL-12 before or after conditional regimen, the protective effects of IL-12 to the bone marrow non-HSC preserve the bone marrow microenvironment, which than provide the supporting system for the transplanted stem cells for their growth and proliferation and maturation. As shown below, with limited non-rescue stem cell number, IL-12 treated bone marrow can support the early engraftment of transplanted stem cells and resulted in the rescue of the lethally irradiated animals.
Injection of IL-12 can facilitate the engraftment of stem cells in stem cell transplantation. When neither non-rescue dose of HSC or non-rescue does of IL-12 can protect animals from lethal dose radiation (mimic the conditional regimen in stem cell transplantation, no animal survived), a combination of the two results in 80% of survival rate. Further more, with IL-12 treatment, the donor cells give earlier and better proliferation after transplantation.
To improve the success of stem cell transplantation, efforts have been put in developing the methods of stem cell in vitro expansion. Other methods, such as co-transplantation of other cellular components or using expanded stem cells have also been reported in animal studies. However, both methods are patient-specific, which needs to isolate cells from patient and treat the cells in vitro. All the procedures are complicated and expansive.
The potential of using IL-12 to protect and facilitate the hematopoiesis has been provided. The inventors show that at a proper dose level, IL-12 can protect the bone marrow hematopioetic system and promote engraftment in BMT without adversely affecting GI system. IL-12 may play its role by affecting the cells in bone marrow microenvironment.
The present invention relates to IL-12 treated, lethally or sublethally irradiated animals that were examined for the survival/life-span, bone marrow cell functional recovery and bone marrow transplantation effect using competitive transplantation, CFU-S12, Colony Forming Cell (CFC), and apoptosis assay.
The invention shows that at a low dose (10 times lower than previously reported dose), 91.4% of lethally irradiated animals survived long-term without adversely affecting the gastro-intestine (GI) system. The reconstituted hematopoietic system was derived from long term repopulating hematopoietic stem cells (LTR HSC), which can reconstitute hematopoiesis both endogenously after lethal radiation and in secondary recipients by bone marrow transplantation (BMT). IL-12 significantly attenuated the decline of blood cell counts in sublethally irradiated animals. The stimulated hematopoiesis recovery resulted in a full lineage blood cell production, including white and red blood cells, and platelets. There was no detectable expression of IL-12 receptor on LTR HSC. In IL-12 treated animals, Sca-1+ cells were significantly higher than animals without IL-12 treatment.
The invention shows that IL-12 may be used as an anti-tumor, anti-angiogenic agent and that the hematopoietic-protecting effects to severe myelosuppression may have clinical significance in cancer treatment and BMT.
To practice methods relating to the administration of compositions comprising IL-12, compositions are formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.
In one embodiment, IL-12 compositions are prepared with carriers that will protect the compounds against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Compositions, may also comprise siRNAs conjugated to cationic polypeptides, amphipathic compounds, polycations, liposomes or PEGlyated liposomes. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. “Dosage unit form,” as used herein, refers to physically discrete units suited as unitary dosages for the subject to be treated, each unit containing a predetermined quantity of an active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
The dosage required for treating a subject depends on the choice of the route of administration, the nature of the formulation, the nature of the subject's illness, the subject's size, weight, surface area, age, and sex, other drugs being administered, and the judgment of the attending physician. Wide variations in the needed dosage are to be expected in view of the variety of compounds available and the different efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization as is well understood in the art. Encapsulation of the compound in a suitable delivery vehicle (e.g., polymeric microparticles or implantable devices) may increase the efficiency of delivery, particularly for oral delivery.
The following examples are intended to illustrate, but not to limit, the scope of the invention. While such examples are typical of those that might be used, other procedures known to those skilled in the art may alternatively be utilized. Indeed, those of ordinary skill in the art can readily envision and produce further embodiments, based on the teachings herein, without undue experimentation.
6 to 8 weeks old C57BL/6J female mice were obtained from Jackson Laboratory (Bar Harbor, Me.) and maintained in the animal facility at University of Southern California (USC, Los Angeles, Calif.) as described previously [32]. The animal study protocol was approved by the University of Southern California Animal Care and Use Committee. Recombinant murine interleukin 12 (rmIL-12) was purchased either from R&D Systems, Inc (Minneapolis, Minn.), or PeproTech Inc (Rocky Hill, N.J.) and was dissolved in phosphate buffered saline (PBS) at 100 ng/μl stock concentration according to the manufacturer's recommendation, and stored at −70° C. Antibodies used in the study were purchased from BD Biosciences (San Jose, Calif.).
rmIL-12 was intravenously (i.v.) injected into mice before or after total body irradiation at the indicated time points. Mice in the control group received PBS. Mice were lethally irradiated with 10 Gy given in two fractions of 5 Gy 3 hours apart using dual, opposed sources of cesium 137 irradiator (Atomic Energy of Canada, Model: γ-cell 40) or one dose of radiation at 10 Gy.
In an experiment to study IL-12 effects to sublethally treated animals, 5 Gy was given to animals 24 hours after IL-12 treatment. Base line blood counts were collected before IL-12 injection. Then, at different times after radiation, blood cell counts were measured.
To determine the peripheral blood cell counts, 10 ul blood was collected from the tail vein, diluted in 490 ul PBS buffer, and then analyzed in a MASCOT Multispecies Hematology Systems (CDC Technologies, Oxford, Conn.).
At different days after lethal dose irradiation, femurs and small intestines were removed from IL-12 treated and control animals and fixed in 10% formalin buffer. The femurs were decalcified in Immunocal Formic Acid Bone Decalcifier (Decal Corporation, NY) for 2 hours. The decalcified femurs and small intestine were embedded in TissuePrep 2 paraffin wax for micro-section at 5 μm and routine Hematoxylin & Eosin staining was performed. Slides were examined under microscope (Nikon E CLPSE E 8000, Camera: Diagnostic Model 2.2.1 with Spot RT software V3.5).
1) After IL-12 administration (100 ng/mouse, 24 hrs before radiation) and irradiation (10 G), bone marrow cells from donor mice (IL-12 treated C57BL/Ly5.2 mice) were isolated at different times post irradiation. Bone marrow cells were flushed out and the red blood cells were lysed as previously described. 1×107 donor cells were transplanted to lethally irradiated recipients (C57BL/Ly5.1, 10 G) to determine the long-term repopulation activity. Mice were observed daily and surviving rate was recorded. There were 10 recipients for each time point.
2) After survival for 6 months after IL-12 treatment, bone marrow cells (C57BL/Ly5.2) were isolated and injected (1×106) to lethally irradiated recipients (C57BL/Ly5.1 mice, 10 G). 4 months after the transplantation, peripheral blood was collected to determine the donor cell derived reconstitution (anti-CD45.2 antibody), donor cell differentiated lymphoid cells (T and B cell with anti-CD3 and anti-B220 antibody) and myeloid cells (macrophage and granulocyte cell with anti-CD11b and anti-Gr1 antibody) via FACS analysis. There were 5 mice in each group.
24 hrs after intravenous injection of IL-12 (100 ng/mouse) or PBS, mice were lethally irradiated (10 Gy, one time exposure). At indicated time after radiation, 2×105 bone marrow cells were collected from the IL-12 treated or control mice and injected to recipient mice, which had received lethal dose irradiation. 12 days after transplantation, recipient mice were sacrificed and the spleens were removed and fixed in Tellyesniczky's solution as described previously [35]. Colonies on the spleen surface were counted. There were three mice in each group. The experiment was repeated twice.
24 hrs after intravenous injection of IL-12 (100 ng/mouse) or PBS, mice were lethally irradiated (10 Gy, one time exposure). At indicated times after radiation, 2×105 bone marrow cells were collected for the assay following the manufacturer's instruction (MethCult GF M3434, StemCell Technologies Inc, Vancouver, BC). 2×104 bone marrow cells from wild type animals were used in the assay. There were three mice in each group; the experiment was repeated twice.
IL-12 receptor expression
Lin−Sca-1+C-kit+CD34− cells were isolated as previous described [33]. In brief, lineage negative cells were stained with anti-Sca-1, anti-c-kit and anti-IL-12 receptor (β2 subunit) for FACS analysis to determine the expression of IL-12 receptor. To perform RT-PCR analysis of IL-12 receptor expression, total RNA was isolated from 4 individual samples with 5000 Lin−Sca-1+c-kit+CD34− cells. First-strand cDNA was synthesized from this RNA following the manufacturer's directions using the SuperScript III First-strand Synthesis System (Invitrogen) using oligo dT primers. Real-time PCR was done using the Roche LightCycler. Crossing points (CPs) of real-time PCR curves were determined by the LightCycler 3.5 software using the second derivative maximum method. PCR reactions were performed using the QuantiTect SYBR Green PCR Master Mix (Qiagen), 0.5 uM each primer and 1 or 2 μl of first-strand reaction (total volume 21 μl). PCR was performed in the LightCycler with 15 min at 95° C. (hotstart) followed by 45 cycles of 15 sec at 94° C., 30 sec at 55° C. and 15 sec at 72° C. Melting curve analysis followed to ensure that there were no primer dimers present and that the correct specific product was made. Primer design was done using Primer 3. For each sample, primers for IL-12 receptor β2 subunit, CD3e and β-actin were used to detect the expression of each corresponding cDNA. Primers used in the reaction are as following:
24 hrs after intravenous injection of IL-12 (100 ng/mouse) or PBS, mice were lethally irradiated (5 Gy×2, 3 hrs interval). Four days after radiation, bone marrow cells (1×106) GFP (Green Fluorescence Protein) transgenic mice (no treatment) were isolated and intravenously transplanted into lethally irradiated mice treated as described above. At 1, 3, 5, 7 and 30 days post transplantation, mice were killed and bone marrow cells were isolated from for FACS analysis for the presence of GFP cells. There were three mice in each group; the experiment was repeated twice.
To determine the stem cell engraftment, the recipient mice received non-protective dose of IL-12 (25 ng/mouse) or PBS. 24 hrs after the treatment, mice received lethally dose radiation (5 Gy×2, 3 hrs interval). Then, the recipient mice were intravenously transplanted with 100 Lin−Sca-1+c-kit+ cells or PBS. The method of 100 Lin−Sca-1+c-kit+ cell purification was described in previous publication [32].
The surviving rate of the transplanted mice was observed daily for 30 days. The results were presented in a Kaplan-Meier plot. There were 5 mice in each group.
Cell apoptosis was analyzed by the TACS Annexin V-FITC Apoptosis Detection Kit (R&D Systems, Minneapolis, Minn.). 3×105 cells were resuspended in the pre-mixed reaction solution containing 1× Binding buffer, Propidium iodide (100 ug/ml), and FITC-conjugated Annexin V of 250 ng/ml. Labeled cells were analyzed by FACS and apoptotic cells were defined as propidium iodide negative and FITC positive cells.
Cell apoptosis was analyzed by the TACS Annexin V-FITC Apoptosis Detection Kit (R&D Systems, Minneapolis, Minn.). 24 hrs after intravenous injection of IL-12 (100 ng/mouse) or PBS, mice were lethally irradiated (5 Gy×2, 3 hrs interval). 4 hrs after the irradiation, bone marrow cells were isolated and stained with FITC-conjugated anti-Annexin V and PE-conjugated anti-Sca-1 or anti-c-kit antibodies.
We analyzed the data by unpaired t-test and Kaplan-Meier and Log-rank test for survival rate.
Low-Dose Il-12 can Rescue Animals from Lethal Dose Irradiation and Promote Bone Marrow Recovery without Adverse Effects on GI
As previously reported, IL-12 mediated radioprotection were achieved with the cost of sensitizing GI system to radiation [15]. It has also been shown that IL-12 mediated GI sensitizing effect is related to IFN-y release, which is dose dependant event [15]. We reasoned that if the radioprotective effects could be achieved with lower dose of IL-12, we might be able to eliminate or significantly decrease the GI damage. First, we performed experiments to determine the optimal minimal dose for IL-12 mediated radioprotection. The tested dose ranged from 5 ng/mouse to 200 ng/mouse. IL-12 was administrated to animals after lethal dose of radiation (spit dose of 10 Gy) and the animal survivals were determined. 10 mice were tested for each dose of IL-12 administration. The minimal dose to achieve the maximum radioprotection (survival) is 100 ng/mouse (5 μg/Kg), which is 10 times lower than the dose used by Neta et. al. [15]. We next tested if the time of administration of IL-12 relative to the time of irradiation resulted in a difference in radioprotection. Varying the administration time of IL-12 relative to the time of irradiation (48, 36, 24 and 12 hrs before radiation; 1 hr, 12, 24 and 36 hrs post radiation), we found that the best rescue effect was achieved when IL-12 was given at 24 hrs before or 1 hr after irradiation. Animal survival rates after lethal irradiation are summarized in
We then evaluated the bone marrow pathological changes of IL-12 treated and control animals at day 1, 3, 5, 7, 12 and 14 post radiation. As shown in
Because of the report of Neta et al. [15], we determined if IL-12 sensitized the GI system to ionizing radiation under the conditions we used (100 ng versus 1000 ng/mouse). With 10 Gy radiation (a hematopoietic lethal dose), the structure and number of villi and crypt from both IL-12-treated (100 ng/mouse) and control mice remained intact (
Since the bone marrow was protected by 100 ng/mouse of IL-12, we investigated whether or not IL-12 decreased the drop in peripheral blood cell count (PBCC). After 10 Gy of radiation, PBCC in both IL-12 treated and control mice dropped to a similar nadir point by day 12, then the PBCC of IL-12-treated mice began to recover while all control mice died (
IL-12 Protects LTR HSC from Lethal Dose Radiation
HSC are a group of heterogeneous cells which contain LTR HSC with full potential of self-renewal ability, short-term reconstituting (STR) HSC with limited self-renewal ability, and progenitor cells without self-renewal ability [32,34]. To determine which subsets of HSC survived the lethal dose radiation and replenished the blood system in IL-12 treated mice, we used different hematopoietic assays to examine the dynamic recovery of HSC activity; BMT to secondary lethally irradiated mice to test LTR HSC activities (
We next investigated if the IL-12 mediated radioprotection was via direct or indirect effect on LTR HSC. Using FACS analysis, we could not detect IL-12 receptor β2 chain expression in Lin−Sca-1+c-kit+ cells (
The integrity of the bone marrow microenvironment is important for stem cell homing and proliferation. A change of microenvironment can affect homing and the proliferation abilities of donor cells in BMT. Using bone marrow cells from GFP (green fluorescent protein) transgenic mice as donor cells, we demonstrated that there was no significant difference in donor cells homing between IL-12-treated and control recipients since there was no difference in the number of donor cells at day 1 and 3 after BMT (
Next, we examined the influence of IL-12 treatment on stem cell transplantation. The experiment was to administer to lethally irradiated mice either a low dose of USC (100 Lin−Sca-1+c-kit+ cells) or a low dose of IL-12 (25 ng/mouse), or the two in combination. Neither low dose stem cell transplantation nor low dose of IL-12 administration alone could rescue lethally irradiated animals. However, the combination rescued 80% of the recipient mice (
IL-12 Protects Sca-1+ Bone Marrow Cells from Lethal Dose Radiation
Radiation induced apoptosis is the major cause of tissue damage [36,37]. To identify which cell subset was protected by IL-12, we performed FACS analysis of cells co-strained for Annexin V and cell type specific markers. Among all the cell surface markers examined (Sca-1, c-kit, CD31, CD105 and Alkaline Phosphotase), we found that after irradiation, the Annexin V−/Sca-1+ cell number was significantly higher in IL-12 treated animals than in control animals (
It this study, we showed that IL-12 could effectively protect animals from lethal radiation and attenuate the decline of the blood cell count after sublethal irradiation without sensitizing the GI system. Further more, we also demonstrated that the replenished blood system after irradiation originated from the LTR HSC. Since there was no detectable IL-12 receptor expression on the LTR HSC, our results suggest that the protective effect from IL-12 may be on the microenvironment or un-identified HSC population which can not be identified with the cell surface markers used in this study (Lin−Sca-1+c-kit+ CD34−). In the BMT experiments, we showed that although the homing efficiency of IL-12 treated or control bone marrow was similar, the donor cells in IL-12 treated bone marrow proliferated more rapidly compared with the cells in control bone marrow, suggesting that the microenvironment of IL-12 treated bone marrow could facilitate the stem cell engraftment.
HSC and its microenvironment in bone marrow are composed of heterogeneous cellular components, which form a precisely organized structural architecture for a complicated structural/functional relationship. Radio-sensitivity is different among various cell types. The LTR HSC is less sensitive to radiation since they are quiescent cells in the Go/G1 phase. It is possible that the lethal dose used in this study did not destroy the LTR HSC, instead, it destroyed cells in microenvironment which are important in supporting and regulating the LTR HSC. Since there was no detectable IL-12 receptor expression in the LTR HSC, it is likely that IL-12 plays its role by protecting the cells in microenvironment that facilitates the recovery of endogenous LTR HSC and the engraftment of HSC in the BMT. The recovered LTR HSC can give rise to a full lineage cell recovery. IL-12 mediated hematopoietic system protection can be a direct effect on the target cells or indirect effect by stimulating the production of other factors that then protects the LTR HSC and/or cells in microenvironment.
There were significantly more Sca-1+ cells in IL-12 treated animals compared to control animals. Although known as a surface marker for HSC, Sca-1 expression has also been reported on the surface of mesenchymal stem cells, endothelial progenitor and osteoblast progenitor cells [39-42]. All are important cellular components of the microenvironment [5,6,8-10, 43, 44]. The protected Sca-1+ cells may be a mixture of several different cell types that function together to restore the microenvironment, which then stimulates the hematopoiesis. Another possibility is that the protected Sca-1+ cells have the property of “multipotent adult progenitor cells” [45] which may give rise to cells that rebuild the BM microenvironment, as well as HSC.
To achieve effective protection of hematopoiesis, IL-12 needs to be administrated in a limited time window relative to the time of irradiation: either 24 hrs before or 1 hr after radiation. In previous studies, most of the factors had to be administrated 24 hrs before irradiation [11-15]. Few reports showed protective effects when factors were given after irradiation [17, 18, 46]. When given 24 hours before radiation, the protective factors may increase the radio-resistance of the target cells. It was proposed that cells at late S-phase of cell cycle are more resistant to radiation [47,48]. When given immediately after irradiation, the factors may function via an anti-apoptosis mechanism by stopping the radiation triggered apoptotic pathway [17,18]. Since IL-12 is effective when administrated both before and after radiation, it may function at multiple levels.
It is commonly accepted that HSC reside in the Lin−Sca-1+c-kit+ population. The lack of Lin−Sca-1+c-kit+ cells after radiation in both IL-12 treated and control animals raise the question of which cell type repopulates the blood system. A HSC subset with positive Sca-1 expression but negative c-kit has been reported [49]. But, these cells can only give delayed reconstitution and cannot rescue lethally irradiated animals. The observed reconstitution in IL-12 protected animals may not be from these cells. It is possible that irradiation down regulates c-kit expression in HSC as it has been reported that cytotoxic agents down regulate the c-kit expression [50].
In summary, this study demonstrated that IL-12 can effectively protect the bone marrow from irradiation and promote the recovery of hematopoiesis. IL-12 can facilitate the donor cell engraftment in BMT. Although there have been reported adverse effects on the GI system from IL-12 mediated IFN-y release, we demonstrated that proper dose control can avoid the onset of this side effect. This study raises the possibility of using IL-12 as an adjuvant therapeutic agent to enhance the recovery of endogenous HSC after radio-/chemo-therapy or to facilitate the engraftment of stem cells in BMT.
Obviously, many modifications and variation of the invention as hereinbefore set forth can be made without departing from the spirit and scope thereof and therefore only such limitations should be imposed as are indicated by the appended claims.
All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
The present application claims the benefit of the filing date of U.S. Provisional Application No. 60/945,280, filed Jun. 20, 2007, the disclosure of which is incorporated herein by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 60945280 | Jun 2007 | US |
